Appointment Announcement: The Estée Lauder Companies has appointed René Lammers, Ph.D., as Executive Vice President and Chief Research & Innovation Officer, effective October 1, 2025, reporting directly to CEO Stéphane de La Faverie.
Role and Responsibilities: Mr. Lammers will lead the company's global Research & Innovation efforts, focusing on product development, scientific affairs, and collaborations with academic institutions, aiming to enhance innovation and sustainability across the brand portfolio.
EL
$104.39+Infinity%1D
Analyst Views on EL
Wall Street analysts forecast EL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EL is 104.06 USD with a low forecast of 70.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast EL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EL is 104.06 USD with a low forecast of 70.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 101.030
Low
70.00
Averages
104.06
High
122.00
Current: 101.030
Low
70.00
Averages
104.06
High
122.00
Citi
Filippo Falorni
Neutral
maintain
$105 -> $110
2025-12-17
New
Reason
Citi
Filippo Falorni
Price Target
$105 -> $110
2025-12-17
New
maintain
Neutral
Reason
Citi analyst Filippo Falorni raised the firm's price target on Estee Lauder to $110 from $105 and keeps a Neutral rating on the shares. The firm adjusted targets in the beverages, household and personal care sector as part of its 2026 outlook. Citi is shifting from a bullish stance on the non-alcoholic beverage space throughout 2025 toward favoring the household and personal care names. It sees improving fundamentals for the group due to the cycling of inventory destocking and easier consumption compares.
Evercore ISI
Robert Ottenstein
Outperform
maintain
$115 -> $125
2025-12-16
New
Reason
Evercore ISI
Robert Ottenstein
Price Target
$115 -> $125
2025-12-16
New
maintain
Outperform
Reason
Evercore ISI analyst Robert Ottenstein raised the firm's price target on Estee Lauder to $125 from $115 and keeps an Outperform rating on the shares. The U.S. market shows supportive signs for Estee's turnaround, with potential upside seen in fiscal Q2, the analyst tells investors.
BofA
NULL -> Strong Buy
upgrade
2025-12-16
New
Reason
BofA
Price Target
2025-12-16
New
upgrade
NULL -> Strong Buy
Reason
BofA analysts added Estee Lauder (EL) to the firm's "US 1 list" while removing AT&T (T). The list represents a collection of BofA's best investment ideas.
BofA
NULL -> Buy
maintain
$120 -> $130
2025-12-16
New
Reason
BofA
Price Target
$120 -> $130
2025-12-16
New
maintain
NULL -> Buy
Reason
BofA raised the firm's price target on Estee Lauder to $130 from $120 and keeps a Buy rating on the shares. Estee Lauder is the analyst's top pick in beauty for 2026 as the firm is encouraged by the "Beauty Reimagined" plan, says the analyst, who cites higher EPS estimates for the firm's raised target. Separately, BofA added Estee Lauder to the firm's "US 1 list," which represents a collection of BofA's best investment ideas.
About EL
The Estee Lauder Companies Inc. is a manufacturer, marketer and seller of skin care, makeup, fragrance and hair care products. Its product categories include skin care, makeup, fragrance, hair care and others. Its products are sold in approximately 150 countries and territories under a number of brand names, including Estee Lauder, Aramis, Clinique, Lab Series, Origins, M.A.C, Bobbi Brown Cosmetics, La Mer, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frederic Malle, GLAMGLOW, Kilian Paris, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD. It is a licensee for fragrances, cosmetics and/or related products for AERIN, BALMAIN, and Dr. Andrew Weil. Its skin care products include moisturizers, serums, cleansers, toners, exfoliators, facial masks, body care, sun care products and others. Its makeup products include lipsticks, lip glosses, mascaras, foundations and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
